The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA discusses the preliminary findings of a Phase I study (NCT03269136) of elranatamab (PF-3135), a bispecific monoclonal antibody, in relapsed/refractory multiple myeloma (MM). Elranatamab targets BCMA, a highly expressed myeloma cell antigen, and CD3, enabling T cell cytotoxic targeting of myeloma cells. Subcutaneous (SC) dose escalation was carried out in 18 patients: no dose-limiting toxicities were observed and the maximum tolerated dose not reached. Adverse events were generally tolerable; the most common was cytokine release syndrome. The overall response rate was 75% when observing the top two dose levels only. SC dose escalation is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
